Abstracts tagged "Anti-TNF therapy and certolizumab pegol"

Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting
Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Gerrit Wolbink^1,2, Philippe Goupille³, William Sandborn⁴, Hubert Marotte⁵, Denis Mulleman³, David Ternant³, Stéphane Paul⁵, Marc de Longueville⁶, Niels Vande Casteele^4,7, Miren Zamacona⁶, Cathy O'Brien⁶, Tore K. Kvien⁸ and Arthur F. Kavanaugh⁹, ¹Amsterdam Rheumatology Immunology Center (ARC), Reade, Amsterdam, Netherlands, ²Department of Immunopathology, Sanquin, Amsterdam, Netherlands, ³Université François-Rabelais, Tours, France, ⁴Division of Gastroenterology, UC San Diego School of Medicine, La Jolla, CA, ⁵Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁶UCB Pharma, Brussels, Belgium, ⁷KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ⁸Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Division of Rheumatology, Allergy & Immunology, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…
Abstract Number: 2589 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Stéphane Paul¹, John Smeraglia², Marc de Longueville², Cathy O'Brien² and Ermis Parussini³, ¹Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ²UCB Pharma, Brussels, Belgium, ³Theradiag, Croissy-Beaubourg, France
Background/Purpose: Measurement of plasma anti-TNF concentration, in combination with the assessment of clinical outcomes, may be used to optimize dosing regimens for individual patients (pts).…
Abstract Number: 503 • 2012 ACR/ARHP Annual Meeting
Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
Xavier Mariette¹, RF. van Vollenhoven², Vivian P. Bykerk³, Marc de Longueville⁴, Catherine Arendt⁴, Kristel Luijtens⁵ and John J. Cush⁶, ¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ²Clinical Trials Unit Department of rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Baylor Research Institute, Dallas, TX
Background/Purpose: The safety of certolizumab pegol (CZP) in rheumatoid arthritis (RA) has been reported in previous pooled analyses of clinical trials. An update of long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].